A cross-border Goodwin Life Sciences team advised a syndicate of investors including Versant Ventures, Dawn Biopharma (a platform controlled by KKR), SR One and Pictet Alternative Advisors on their investment into the €80 Million Series A Financing of Antag Therapeutics. Other investors in the round included Novo Holdings, Longview Ventures (an affiliate of Broadview Ventures), and Export and Investment Fund of Denmark (EIFO). Versant Ventures led the round.
Antag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs. The funds will support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR), and also fueling the expansion of Antag's pipeline of monthly injectable therapies.
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm's emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs.
Dawn is an investment platform controlled by the KKR Healthcare Strategic Growth Fund II, established to own a diverse portfolio of companies committed to the development of innovative medicines and therapies.
SR One is a biotechnology venture capital firm, partnering with founders and entrepreneurs to translate innovative science into medicines.
Pictet Alternative Advisors is an independent unit within the Pictet Group that manages direct and indirect investments in hedge funds, private equity and real estate assets for both private and institutional clients. Pictet employs nearly 200 alternative investment specialists and manages USD 46 billion, with USD 27 billion in private equity, USD 14 billion in hedge funds, USD 4 billion in real estate assets and USD 1 billion in private debt (as of September 2024).
The Goodwin deal team consisted of Sophie McGrath, Lucy Thomas, Amie Corry and Folakemi Dele-Adeniyi (London), and Robert Puopolo, Mayan Katz, Ana Carolina Zattar (US).
For more details on the financing, please see the press release here.
Antag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. As a pioneer in exploring the potential of GIP receptor antagonists, the company is dedicated to advancing science and improving patient outcomes by delivering groundbreaking solutions that address unmet medical needs. The funds will support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR), and also fueling the expansion of Antag's pipeline of monthly injectable therapies.
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm's emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $5.5 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm's founding in 1999, more than 100 Versant companies have achieved successful acquisitions or IPOs.
Dawn is an investment platform controlled by the KKR Healthcare Strategic Growth Fund II, established to own a diverse portfolio of companies committed to the development of innovative medicines and therapies.
SR One is a biotechnology venture capital firm, partnering with founders and entrepreneurs to translate innovative science into medicines.
Pictet Alternative Advisors is an independent unit within the Pictet Group that manages direct and indirect investments in hedge funds, private equity and real estate assets for both private and institutional clients. Pictet employs nearly 200 alternative investment specialists and manages USD 46 billion, with USD 27 billion in private equity, USD 14 billion in hedge funds, USD 4 billion in real estate assets and USD 1 billion in private debt (as of September 2024).
The Goodwin deal team consisted of Sophie McGrath, Lucy Thomas, Amie Corry and Folakemi Dele-Adeniyi (London), and Robert Puopolo, Mayan Katz, Ana Carolina Zattar (US).
For more details on the financing, please see the press release here.